Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-­releasing hormone (GnRH) antagonists have been approved for this indication. 

GnRH analogs are primarily indicated for the preoperative management of uterine fibroids, largely because of their unfavorable long- term adverse effect profile. The previously approved therapy with ulipristal acetate had to undergo extensive restrictions because of safety concerns. 

Nevertheless, there are additional medications that may be used in clinical practice. These include combined oral contraceptives, oral progestins, the levonorgestrel-­releasing intrauterine system (LNG-­IUS), and tranexamic acid. 

Although not specifically approved for the treatment of fibroids, these agents can reduce the intensity of bleeding in cases of heavy menstrual bleeding and thereby improve symptoms and lead to an improved quality of life for the patients.

尽管子宫肌瘤是一种普遍疾病，但获批的药物治疗方案仍然有限。事实上，仅有少数药物被正式批准用于子宫肌瘤的治疗。在美国和欧洲药品管理局管辖区域，部分促性腺激素释放激素（GnRH）拮抗剂已获准用于此适应症。

GnRH类似物主要适用于子宫肌瘤的术前管理，这主要是由于其长期不良反应不容忽视。此前获批的醋酸乌利司他疗法因安全性问题不得不受到严格限制。

尽管如此，临床实践中仍可应用其他药物。这些药物包括复方口服避孕药、口服孕激素、左炔诺孕酮宫内缓释系统以及氨甲环酸。

虽然这些药物并未被特别批准用于治疗子宫肌瘤，但它们能够减轻月经过多病例的出血严重程度，从而改善症状并提升患者的生活质量。